site logo

CFO in the Know: Bright spots for biopharma IPOs, but COVID-19 still lurks

The pandemic has helped the atmosphere for biopharma IPOs by changing the focus of drugs from the downside of their pricing to the benefits they offer of better diagnostics and potential cures.